Estimations des analystes de Wall Street pour Caris Life Sciences, Inc. (CAI): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 6 |
| Conserver | 1 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 7 |
| Note moyenne (1-5) | 0.86 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.03 | ||
| 2026-08-05 | $-0.00 | $0.01 | -139.2% |
| 2026-05-07 | $-0.00 | $-0.02 | +91.0% |
| 2026-02-26 | $0.28 | $0.01 | +2700.0% |
| 2025-11-05 | $0.08 | $-0.08 | +200.0% |
| 2025-08-12 | $-0.54 | $-0.21 | -157.1% |
| 2025-06-09 | $-0.35 | $-0.22 | -60.3% |
| 2021-11-05 | $2.95 | $0.61 | +383.6% |
Ratios de valorisation
| Ratio P/E | 94.25 |
| Prix / Valeur comptable | 16.76 |
| EV / EBITDA | 45.27 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $249.7M | $294.4M | $348.4M | $432.1M | $416.5M | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Coût des Ventes | $123.8M | $156.9M | $179.1M | $218.5M | $216.0M | $109.9M | $178.5M | $216.8M | $233.5M | $272.9M |
| Marge Brute | $125.9M | $137.5M | $169.3M | $213.6M | $200.5M | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| R&D | 0 | 0 | 0 | 0 | 0 | 0 | $101.3M | $116.9M | $113.9M | $45.3M |
| Frais Généraux | $27.6M | $35.7M | $42.7M | $50.3M | $52.7M | $27.3M | $294.5M | $291.5M | $321.9M | $392.5M |
| Charges Opérationnelles | $57.8M | $71.5M | $63.6M | $64.8M | $70.2M | $45.1M | $395.8M | $408.9M | $435.9M | $494.1M |
| Résultat Opérationnel | $68.1M | $66.0M | $105.7M | $148.8M | $130.3M | $139.1M | -$315.8M | -$319.6M | -$257.1M | $45.1M |
| EBITDA | $181.4M | $159.3M | $223.5M | $283.3M | $248.3M | $254.5M | -$245.9M | -$260.8M | -$183.0M | $11.4M |
| Charges d'Intérêt | $36.0M | $42.8M | $53.1M | $78.3M | $79.2M | $61.6M | $26.7M | $31.6M | $50.0M | $56.9M |
| Résultat Avant Impôts | $31.2M | $9.9M | $57.2M | $81.5M | $55.2M | $29.5M | -$320.8M | -$341.4M | -$281.9M | -$68.1M |
| Impôts | $4.3M | $3.8M | -$14.9M | $2.9M | $4.2M | $1.8M | 0 | 0 | 0 | $469.9M |
| Résultat Net | $26.8M | $6.0M | $72.1M | $78.6M | $31.0M | $27.7M | -$320.8M | -$341.4M | -$281.9M | -$538.0M |
| BPA | $1.29 | $0.31 | $3.74 | $3.97 | $1.72 | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.91 |
| BPA Dilué | $1.28 | $0.31 | $3.68 | $3.97 | $1.72 | $1.55 | $-1.57 | $-1.82 | $-2.70 | $-1.86 |
| Actions en Circulation (Diluées) | $21.0M | $19.4M | $19.6M | $19.8M | $18.0M | $17.9M | $254.8M | $254.7M | $254.7M | $289.9M |
Prix
| Prix | $30.92 |
| Capitalisation | $8.7B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CAI: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions